TuHURA Biosciences, Inc. (NASDAQ: HURA) reported its financial results for the three months ended September 30, 2026, and provided a corporate update regarding its immuno-oncology pipeline. The company reported cash and cash equivalents of $1.9 million as of September 30, 2026. During the quarter, TuHURA received $9.2 million in gross proceeds from its Parkview credit facility. Research and development expenses for the quarter were $3.7 million, a decrease of $1.3 million compared to the same period in 2025, attributed to lower manufacturing costs. General and administrative expenses were $2.0 million for the quarter, an increase of $0.4 million compared to 2025, primarily due to non-cash stock compensation and public company costs.
In corporate news, TuHURA announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase 1b study of its VISTA-inhibiting antibody, TBS-2025. The study will evaluate the safety and potential efficacy of the drug as a monotherapy in patients with relapsed/refractory mutated NPM1 acute myeloid leukemia (AML) who have failed Menin inhibitor therapy. The company also highlighted preliminary data from its open-label study of IFx-2.0, an innate immune agonist used with Keytruda, showing major objective partial responses in the first three patients with deep-seated metastatic Merkel Cell Carcinoma, with responses ongoing for more than six months.
Additionally, TuHURA disclosed that it has secured a $50 million credit facility from its largest shareholder, which has allowed the company to fund operations in a non-dilutive manner. The company also announced that it will present three poster presentations at the upcoming American Society of Hematology (ASH) Annual Meeting in New Orleans in December 2026, focusing on its Delta Opioid Receptor (DOR) technology. The company also received new U.S. patents for its VISTA Inhibitor and DOR Antibody Drug Conjugate technology, with patent terms extending through 2042 and 2043, respectively.
